Mycobacterium Tuberculosis Treatment Market Status, Analysis and Business Outlook 2022 to 2031Posted by sandeep gade on November 24th, 2022 As assessed by Persistence Market Research, mycobacterium tuberculosis treatment for active tuberculosis (TB) accounted for a market value of US$ 1.35 Bn in 2021. Overall, mycobacterium tuberculosis drug sales accounted for approximately 2.7% revenue share of the global infectious disease treatment market in 2021. The global market for mycobacterium tuberculosis treatment recorded a historic CAGR of 9.5% in the last 9 years from 2012 to 2021. According to WHO, 1.6 million persons worldwide died from tuberculosis (TB) in 2021. Following COVID-19 and HIV/AIDS, TB is the second infectious killer in the world and the 13th-largest cause of death overall. Globally, 10.6 million cases of tuberculosis (TB) were reported in 2021, which included around 6 million males, approximately 3.4 million females, and more than 1 million children. In March 2021, the World Health Organization published data in a journal titled "Impact of the COVID-19 pandemic on TB diagnosis and mortality in 2020," which revealed that 1.4 million fewer people than in 2019 received TB treatment in 2020, a 21% decline from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease in June 2021 titled "The impact of COVID-19 on TB: a review of the data”, it was noted that the provision of tuberculosis services has been hampered by a high TB burden due to inadequate equipment and capacity, restrictions on migration (affecting supplies, and healthcare staff), and resource reallocation. Despite the negative impact of COVID-19 on the overall market, it is set to exhibit growth over the coming years. Also, due to factors such as governments’ challenges and the National Strategic Plan to eradicate tuberculosis by 2025, the market is likely to show steady growth over the coming years. Competitive Landscape Key players in the mycobacterium tuberculosis treatment industry are engaged in activities such as new product launches, acquisitions, collaborations, and expansion for the advancement and development of new products and therapies. For instance, In August 2022, Janssen Pharmaceutica NV, Otsuka Pharmaceutical Co., Ltd. Evotec, GSK, and the Bill & Melinda Gates Foundation collaborated with the Project to Accelerate New Treatments for Tuberculosis (PAN-TB) for combination treatment regimens into phase 2 clinical development. In September 2021, Lupin Limited received a non-exclusive license grant from nonprofit drug developer, TB Alliance to manufacture the anti-TB drug pretomanid and commercialized it in 140 countries, especially in the highest TB burden countries around the world. Buy Full Report Now and Get Up to 20% Discount: Like it? Share it! More by this author |